Latest news
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary - TradingViewTradingView · Fri, 07 Aug 2026 20:51:12 GMTBIAF: Strong CyPath® Lung growth drives Q2 2026, but liquidity concerns persist amid ongoing losses - TradingViewTradingView · Fri, 07 Aug 2026 20:49:59 GMTBIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss - TradingViewTradingView · Fri, 07 Aug 2026 12:36:27 GMTbioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M - TradingViewTradingView · Fri, 07 Aug 2026 12:33:01 GMTEnterprise value to EBITDA forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingViewTradingView · Wed, 05 Aug 2026 00:10:44 GMTBF Investment Limited Revenue Breakdown – NSE:BFINVEST - TradingViewTradingView · Sat, 01 Aug 2026 06:18:05 GMTbioAffinity Technologies Received Notice of Delisting - TradingViewTradingView · Fri, 31 Jul 2026 21:23:01 GMTBF Biosciences Ltd Revenue Breakdown – PSX:BFBIO - TradingViewTradingView · Mon, 27 Jul 2026 14:49:28 GMT